4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Parabilis Medicines, Inc. (PBLS) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 145 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2025-12-31, PBLS reported $0M in revenue and ($146M) in net income.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Revenue | $0M | $0M |
| Operating Income (EBIT) | ($152M) | ($126M) |
| Net Income | ($146M) | ($118M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-03-31 |
|---|---|---|
| Total Revenue | $0M | $0M |
| Operating Income (EBIT) | ($48M) | ($40M) |
| Net Income | ($45M) | ($38M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Assets | $81M | $149M |
| Total Liabilities | $97M | $93M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PBLS viewer.
About TickerBase · Data methodology & sources